In summary, JWA, XRCC1 and BRCA1 mRNA expression as predictive markers could be used in molecular staging for personalized therapy in ESCC patients who received first-line cisplatin or docetaxel-based treatments. This evidence concerns the gene XRCC1 and esophageal squamous cell carcinoma.